argenx SE (NASDAQ:ARGX) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of argenx SE (NASDAQ:ARGX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the twenty-three research firms that are covering the firm, Marketbeat reports. Three investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $699.28.

A number of equities research analysts have weighed in on the company. Oppenheimer raised their price target on argenx from $675.00 to $704.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. HC Wainwright reissued a "buy" rating and set a $720.00 target price on shares of argenx in a research note on Tuesday, April 8th. Guggenheim raised their price objective on shares of argenx from $775.00 to $1,100.00 and gave the stock a "buy" rating in a report on Monday, March 10th. Wells Fargo & Company boosted their target price on argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Finally, Sanford C. Bernstein upgraded shares of argenx from a "market perform" rating to an "outperform" rating in a research note on Monday, March 17th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. GeoWealth Management LLC increased its stake in argenx by 56.3% in the 4th quarter. GeoWealth Management LLC now owns 50 shares of the company's stock valued at $31,000 after buying an additional 18 shares during the period. Steward Partners Investment Advisory LLC boosted its stake in shares of argenx by 5.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company's stock worth $234,000 after purchasing an additional 20 shares during the last quarter. SG Americas Securities LLC grew its stake in argenx by 6.2% in the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company's stock worth $220,000 after acquiring an additional 21 shares during the period. Farther Finance Advisors LLC grew its position in shares of argenx by 38.2% in the fourth quarter. Farther Finance Advisors LLC now owns 76 shares of the company's stock valued at $47,000 after purchasing an additional 21 shares during the period. Finally, Greenleaf Trust raised its stake in argenx by 3.5% during the first quarter. Greenleaf Trust now owns 624 shares of the company's stock worth $369,000 after purchasing an additional 21 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Stock Performance

argenx stock traded down $3.28 during midday trading on Friday, reaching $641.86. 21,576 shares of the stock were exchanged, compared to its average volume of 307,767. argenx has a 52 week low of $352.77 and a 52 week high of $679.92. The firm has a market cap of $39.19 billion, a PE ratio of -728.13 and a beta of 0.60. The company's fifty day moving average is $597.55 and its 200-day moving average is $609.98.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. The company had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. On average, sell-side analysts anticipate that argenx will post 3.13 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.